Partner Headlines - BIIB

  1. Citi, Jefferies Weigh In On Biogen Idec Amid Q3 Earnings

    Benzinga
  2. US Stock Futures Rise Ahead Of Earnings, Economic Data

    Benzinga
  3. Leading Researchers Join Biogen Idec To Advance Drug Discovery ...

    Benzinga
  4. Better Biotechs Don't Satisfy

    IBD
  5. Biotechs Show Fed Chief's Not Much Of A Stock Analyst

    IBD
  6. Markets Reverse Early Morning Gains Following Canadian Shooting

    Benzinga
  7. Major Indexes End Win Streak; Super Micro Surges

    IBD
  8. Stocks Erase Modest Gains; Apple Flirts With Breakout

    IBD
  9. Stocks Up at Midday; Super Micro Retakes Buy Point

    IBD
  10. Biogen, Thermo Reports Disappoint; Abbott Accelerates

    IBD
  11. Stocks Cling To Slender Advance; Boeing, Cree, Biogen Slide

    IBD
  12. Morning Market Losers

    Benzinga
  13. Benzinga's Top #PreMarket Losers

    Benzinga
  14. UPDATE: Biogen Idec Posts Upbeat Q3 Results, Raises Earnings ...

    Benzinga
  15. Earnings Scheduled For October 22, 2014

    Benzinga
  16. Biogen Leads 5 Top Biotech Stocks As Earnings Loom

    IBD
  17. Yahoo, Super Micro Rally After Hours

    IBD
  18. Celgene Reports More Good Crohn's Disease Data

    IBD
  19. Celgene's Crohn's Disease Drug Hits Its Marks

    IBD
  20. Celgene, Alexion Among 4 IBD 50 Medical s To Report

    IBD
  21. Baxter Q3 Beats As Hemophilia Drugs Fend Off Rivals

    IBD
  22. IPO Stock Watch: Biotech Forward Pharma Falls On IPO

    IBD
  23. Major Averages Pare Losses, Then Head Lower Again

    IBD
  24. IBD 50: Medical, Internet Companies Top Q3 Estimates

    IBD
  25. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  26. Which Fund Has The Most To Gain From Biogen Idec?

    Benzinga
  27. IBD 50: Medical, Internet Companies Top Q3 Profit Estimates

    IBD
  28. Most Top Industry Groups Fall Harder Than Market

    IBD
  29. Biogen Idec Inc's Stock Is Set To Drop

    Benzinga
  30. Second Oldest Stock Fund Is As Nimble As A Teenager

    IBD
  31. Top Fund Buys: Chipotle, Allergan, Jazz, Gilead

    IBD
  32. Ebola Diagnosis in U.S. Raises Pharmaceutical Stock by 20%

    GuruFocus
  33. Biogen Idec Inc Still Showing Relative Weakness Compared To Biotech ...

    Benzinga
  34. Biotech Stocks Rebound On Strong Earnings, New Drugs

    IBD
  35. Large-Cap Tech, Biotech Names Hang Tough In Shaky Market

    IBD
  36. New MS Drugs Offer Promise

    IBD
  37. Multiple Sclerosis Drugs Could Transform Market Again

    IBD
  38. Technology Stocks Slide But Other Sectors Hold Up Better

    IBD
  39. A Few Reasons Why AbbVie's Momentum Will Continue

    GuruFocus
  40. Stocks Get Hit Hard; GoPro, Skechers Buck Weakness

    IBD
  41. Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains

    IBD
  42. Apple Fuels Tech Sell-Off; Valeant Bucks The Trend

    IBD
  43. Stocks End Skid; Vertex, Alexion Lead Biotech Rebound

    IBD
  44. Stocks Up In Afternoon; Hasbro Jumps On Disney Deal

    IBD
  45. Acorda To Buy Civitas, Gains Parkinson's Disease Drug

    IBD
  46. Stocks Hold Solid Gains; CyberArk Soars In Debut

    IBD
  47. Most Big Cap 20 Stocks Near Entries, But Risks Exist

    IBD
  48. Gilead's Zydelig Approved In EU; Imbruvica In Wings

    IBD
  49. 2 Columbia Growth Funds Notch Impressive Three-Month Performance

    Benzinga
  50. Nasdaq Falls Hard, But Apple Resilient On iPhone Orders

    IBD
  51. Gilead, Jazz, Salix Among Top 6 IBD 50 Drugmakers

    IBD
  52. Why Nine of Fifteen Oil Majors Are Undervalued

    YCharts
  53. Medivation Eyes Blockbuster As Cancer Drug Gets An OK

    IBD
  54. Stocks Show Modest Losses; Biotechs Pressured Again

    IBD
  55. Biogen Idec Inc Suddenly Struggling To Keep Up With The Biotech ...

    Benzinga
  56. Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of ...

    Benzinga
  57. Biogen Announces Five-Year Results from ENDORSE Phase 3 Study ...

    Benzinga
  58. Stocks Turn Higher After Soft Start; U.S. Silica Jumps

    IBD
  59. ReceptosMS Drug Yields More Good Data; Stock Jumps

    IBD
  60. Steadier, Better: 35 Years Of Low-Volatility Stocks

    YCharts
  61. Allianz's Analyst Likes Biogen, Celgene & Gilead

    Benzinga
  62. Indexes Trim Losses But Remain Lower At Midday

    IBD
  63. Biogen: Moving From Collaboration To Innovation

    IBD
  64. Economic Data Fuel Another All-Time High For S&P 500

    IBD
  65. Celgene, Gilead Lead Big Biotech Stock Movers

    IBD
  66. Biogen, Celgene In Buy Range; LinkedIn Coming Back

    IBD
  67. Stocks Hold Decent Gains; InterMune Deal Sparks Biotechs

    IBD
  68. Majority Of IBD 50 Firms Strong On Sponsorship

    IBD
  69. Biogen's buy rating reaffirmed

    IBD
  70. UPDATE: Morgan Stanley Reiterates On Biogen Idec Following Plegridy ...

    Benzinga
  71. Perrigo Regains Some Lost Ground On Fiscal Q4 Beat

    IBD
  72. Perrigo Q4 Beats Estimates, But Guidance Misses

    IBD
  73. Tech, Health Care Lead Q2 Earnings Beats

    IBD
  74. #PreMarket Primer: Friday, August 8: U.S. To Begin Airstrikes ...

    Benzinga
  75. Top 4 Stocks In The Biotechnology Industry With The Highest Revenue

    Benzinga
  76. Why Investors Should Closely Watch Celgene

    Benzinga
  77. Biotech Gets A Lift On Popular Drug, Strong Pipeline

    IBD
  78. Ken Fisher's Top Increaes of the Second Quarter

    GuruFocus
  79. Ken Fisher's Top Increases of the Second Quarter

    GuruFocus
  80. Chipotle, Facebook Rally On Upside Earnings Surprise

    IBD
  81. Celgene, Alexion Beat Estimates, But Biotechs Fall

    IBD
  82. Celgene, Alexion Earnings Top Street, But Stocks Fall

    IBD
  83. Biogen, Gilead Profits Soar

    IBD
  84. Biogen, Gilead Crush Earnings Estimates On Hot Drugs

    IBD
  85. S&P 500 Posts New High; Biotechs, Airlines, Builders Up

    IBD
  86. IPO Stock Watch: Biotechs Are Half Of July Calendar

    IBD
  87. Vertex Is Poised For An Earnings Breakout

    Benzinga
  88. Pepsi Beats; Positive Phase 3 Breast Cancer Data Creates Potential ...

    Benzinga
  89. S&P 500 Flirts With High; Breadth Missing On Nasdaq

    IBD
  90. Intuitive Surgical Rises On Upbeat Earnings; Xilinx Shares Slip

    Benzinga
  91. S&P 500 Aims At New High; Biotechs Gap Up In Fast Trade

    IBD
  92. Biogen Trounces Q2 Estimates As Tecfidera Outperforms

    IBD
  93. Apple, Microsoft Lead Nasdaq Higher; Dow Falters

    IBD
  94. Markets Mixed; PepsiCo Q2 Earnings Beat Street View

    Benzinga
  95. Stocks: Mixed Open, Mixed Trade; Delta, Broadcom, Biogen Buck ...

    IBD
  96. Morning Market Movers

    Benzinga
  97. UPDATE: Biogen Idec Posts Stronger-Than-Expected Q2 Results, ...

    Benzinga
  98. Stock Futures Up, But Wobbly; Boeing, Apple, Biogen Rising

    IBD
  99. Benzinga's Top #PreMarket Gainers

    Benzinga
  100. Earnings Scheduled For July 23, 2014

    Benzinga
Trading Center